

Sinus Disease in Young Children With Cystic Fibrosis

NCT06191640

Status	RECRUITING
Sponsor	University of California, Los Angeles
Enrollment	80 participants

Key Eligibility Criteria

Inclusion (9)

- HEMT Group:
 - Children with documentation of a CF diagnosis
 - Age 2-8 years old at first study visit
 - CFTR mutation consistent with FDA labeled indication of highly effective modulator therapy (ivacaftor or elexacaftor/tezacaftor/ivacaftor)
 - Clinician intent to prescribe ivacaftor or ETI so that enrollment is before start of HEMT
- ... and 4 more (see full listing online)

Exclusion (5)

- For Both Groups:
- Use of an investigational drug within 28 days prior to the first study visit
- Use of ivacaftor or elexacaftor/tezacaftor/ivacaftor within the 180 days prior to and including the first study visit
- Use of chronic oral corticosteroids within the 28 days prior to and including the first study visit.
- Sinus surgery within 180 days prior to the first study visit

Locations (6 total)

Children's Hospital Colorado, Aurora, Colorado, United States
University of Iowa, Iowa City, Iowa, United States
University of Kansas Medical Center, Kansas City, Kansas, United States
... and 3 more locations